Patient | Net quantitative enhancement | Per-ROI average quantitative enhancement | ||||
---|---|---|---|---|---|---|
Gadoteridol | Gadobutrol | Difference | Gadoteridol | Gadobutrol | Difference | |
1 | 2,660.6 | 2,355.5 | 305.1 | 0.096 | 0.085 | 0.011 |
2 | 225.3 | 196.1 | 29.1 | 0.040 | 0.034 | 0.005 |
3 | 7,421.5 | 6,814.4 | 607.1 | 0.139 | 0.128 | 0.011 |
4 | 1,829.6 | 1,533.0 | 296.6 | 0.113 | 0.095 | 0.018 |
5 | 736.3 | 949.3 | -213.0 | 0.163 | 0.210 | − 0.047 |
6 | 1,836.3 | 1,635.1 | 201.1 | 0.211 | 0.188 | 0.023 |
7 | 2,306.0 | 2,816.1 | -510.1 | 0.130 | 0.159 | − 0.029 |
8 | 711.3 | 695.5 | 15.8 | 0.176 | 0.172 | 0.004 |
9 | 2,445.9 | 2,225.5 | 220.4 | 0.093 | 0.084 | 0.008 |
10 | 3,755.9 | 3,356.3 | 399.6 | 0.380 | 0.339 | 0.040 |
11 | 9,759.5 | 9,814.0 | -54.5 | 0.217 | 0.218 | − 0.001 |
12 | 596.4 | 534.8 | 61.6 | 0.089 | 0.079 | 0.009 |
13 | 2,326.9 | 2,505.6 | -178.7 | 0.184 | 0.198 | − 0.014 |
14 | 308.1 | 317.2 | -9.1 | 0.065 | 0.067 | − 0.002 |
15 | 1,255.6 | 1,082.3 | 173.3 | 0.102 | 0.088 | 0.014 |
16 | 280.5 | 226.9 | 53.6 | 0.039 | 0.031 | 0.007 |
17 | 2,353.9 | 2,640.1 | -286.2 | 0.182 | 0.205 | − 0.022 |
18 | 277.3 | 248.1 | 29.2 | 0.187 | 0.167 | 0.020 |
19 | 364.5 | 304.8 | 59.8 | 0.072 | 0.060 | 0.012 |
20 | 13,009.7 | 1,5861.3 | -2851.6 | 0.159 | 0.194 | − 0.035 |
21 | 142.0 | 129.9 | 12.1 | 0.107 | 0.098 | 0.009 |
22 | 1,247.2 | 873.2 | 374.0 | 0.172 | 0.120 | 0.052 |
23 | 2119.5 | 2,103.0 | 16.6 | 0.190 | 0.189 | 0.001 |
24 | 230.1 | 164.5 | 65.6 | 0.041 | 0.029 | 0.012 |
25 | 1,339.9 | 1,539.6 | -199.7 | 0.148 | 0.170 | − 0.022 |
26 | 1,453.5 | 1,402.2 | 51.3 | 0.060 | 0.058 | 0.002 |
27 | 1,307.5 | 634.4 | 673.1 | 0.057 | 0.028 | 0.029 |
Mean ± SD | 2,307.4 ± 3,045.4 | 2,331.8 ± 3,445.4 | -24.4 ± 620.8 | 0.134 ± 0.074 | 0.129 ± 0.076 | 0.004 ± 0.022 |
p-value* | Â | Â | 0.840 | Â | Â | 0.313 |